𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase II trial of paclitaxel (Taxol®) as first line treatment in advanced breast cancer

✍ Scribed by Sandra M. Swain; Susan F. Honig; Mariella C. Tefft; Linda Walton

Publisher
Springer US
Year
1995
Tongue
English
Weight
467 KB
Volume
13
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Mitoxantrone as a first-line treatment o
Mitoxantrone as a first-line treatment of advanced breast cancer
✍ Karl Landys; Stig Borgstrom; Torsten Andersson; Henry Noppa 📂 Article 📅 1985 🏛 Springer US 🌐 English ⚖ 354 KB

Forty-two Women with measurable or evaluable advanced breast cancer who had received neither prior chemotherapy for advanced disease nor any anthracycline-containing regimen as adjuvant were entered in a phase II study of mitoxantrone (Novantrone| dihydroxyanthracenedione). Patients were aged from 3

A phase II study of paclitaxel plus carb
A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma
✍ Edith A. Perez; David W. Hillman; Philip J. Stella; James E. Krook; Lynn C. Hart 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB 👁 3 views

## BACKGROUND. This Phase II multicenter study evaluated the efficacy and toxicity of paclitaxel (200 mg/m 2 by 3-hour infusion) with carboplatin (area under the curve 6 mg/mL per minute) administered every 3 weeks as first-line therapy for women with metastatic breast carcinoma. ## METHODS. Eligi

Mitoxantrone as first-line chemotherapy
Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study
✍ H. T. Mouridsen; Michael Cornbleet; Robin Stuart-Harris; Ian Smith; Robert Colem 📂 Article 📅 1985 🏛 Springer US 🌐 English ⚖ 565 KB

Mitoxantrone (Novantrone| dihydroxyanthracenedione) is a substituted anthraquinone with a spectrum of activity similar to doxorubicin in experimental tumors. One hundred and seventy three patients with advanced breast cancer and no prior cytotoxic therapy for advanced disease entered a phase II stu